New use for cannabinoid

Roger Guy Pertwee (Inventor), Geoffrey W Guy (Inventor)

Research output: Patent

Abstract

The cannabinoid tetrahydrocannabidivarin (THCV) acts as a neutral antagonist of the CB1 cannabinoid receptor, and may be used for the treatment of obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimers disease, bone disorders, obesity associated with type II (non-insulin dependent) diabetes) or in the treatment of drug, alcohol or nicotine abuse or dependency. THCV may also be used as an appetite suppressant for cosmetic weight loss. THCV may be prepared as a crude extract from a cannabis plant, a purified product or a synthetic molecule. Other neutral antagonists of the CB1 receptor may also be used for the treatment of CB1 related conditions.
Original languageEnglish
Patent numberBRPI0518011
IPCA61K31/00; A61K31/33; A61K31/454;
Publication statusPublished - 21 Oct 2008

Fingerprint

Cannabinoid Receptor CB1
Cannabinoids
Obesity
Cannabinoid Receptor Antagonists
Appetite Depressants
Cannabis
Complex Mixtures
Nicotine
Cosmetics
Weight Loss
Epilepsy
Schizophrenia
Alzheimer Disease
Alcohols
Bone and Bones
Pharmaceutical Preparations
Dependency (Psychology)

Cite this

Pertwee, R. G., & Guy, G. W. (2008). IPC No. A61K31/00; A61K31/33; A61K31/454; . New use for cannabinoid. (Patent No. BRPI0518011).

New use for cannabinoid. / Pertwee, Roger Guy (Inventor); Guy, Geoffrey W (Inventor).

IPC No.: A61K31/00; A61K31/33; A61K31/454; . Patent No.: BRPI0518011.

Research output: Patent

Pertwee, RG & Guy, GW 2008, New use for cannabinoid, Patent No. BRPI0518011, IPC No. A61K31/00; A61K31/33; A61K31/454; .
Pertwee RG, Guy GW, inventors. New use for cannabinoid. A61K31/00; A61K31/33; A61K31/454; . 2008 Oct 21.
Pertwee, Roger Guy (Inventor) ; Guy, Geoffrey W (Inventor). / New use for cannabinoid. IPC No.: A61K31/00; A61K31/33; A61K31/454; . Patent No.: BRPI0518011.
@misc{89824734121f40aebbce726448f10262,
title = "New use for cannabinoid",
abstract = "The cannabinoid tetrahydrocannabidivarin (THCV) acts as a neutral antagonist of the CB1 cannabinoid receptor, and may be used for the treatment of obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimers disease, bone disorders, obesity associated with type II (non-insulin dependent) diabetes) or in the treatment of drug, alcohol or nicotine abuse or dependency. THCV may also be used as an appetite suppressant for cosmetic weight loss. THCV may be prepared as a crude extract from a cannabis plant, a purified product or a synthetic molecule. Other neutral antagonists of the CB1 receptor may also be used for the treatment of CB1 related conditions.",
author = "Pertwee, {Roger Guy} and Guy, {Geoffrey W}",
year = "2008",
month = "10",
day = "21",
language = "English",
type = "Patent",
note = "BRPI0518011; A61K31/00; A61K31/33; A61K31/454;",

}

TY - PAT

T1 - New use for cannabinoid

AU - Pertwee, Roger Guy

AU - Guy, Geoffrey W

PY - 2008/10/21

Y1 - 2008/10/21

N2 - The cannabinoid tetrahydrocannabidivarin (THCV) acts as a neutral antagonist of the CB1 cannabinoid receptor, and may be used for the treatment of obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimers disease, bone disorders, obesity associated with type II (non-insulin dependent) diabetes) or in the treatment of drug, alcohol or nicotine abuse or dependency. THCV may also be used as an appetite suppressant for cosmetic weight loss. THCV may be prepared as a crude extract from a cannabis plant, a purified product or a synthetic molecule. Other neutral antagonists of the CB1 receptor may also be used for the treatment of CB1 related conditions.

AB - The cannabinoid tetrahydrocannabidivarin (THCV) acts as a neutral antagonist of the CB1 cannabinoid receptor, and may be used for the treatment of obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimers disease, bone disorders, obesity associated with type II (non-insulin dependent) diabetes) or in the treatment of drug, alcohol or nicotine abuse or dependency. THCV may also be used as an appetite suppressant for cosmetic weight loss. THCV may be prepared as a crude extract from a cannabis plant, a purified product or a synthetic molecule. Other neutral antagonists of the CB1 receptor may also be used for the treatment of CB1 related conditions.

M3 - Patent

M1 - BRPI0518011

ER -